Roivant (ROIV) CFO nets 1,235 RSU shares for taxes in Form 4

Roivant Sciences Ltd. (ROIV) reported an insider equity transaction by its Chief Financial Officer.

Rhea-AI Filing Summary

Roivant Sciences Ltd. (ROIV) reported an insider equity transaction by its Chief Financial Officer. On 11/20/2025, the CFO had 1,235 common shares withheld at a price of $20.27 per share. This was a "net settlement" of previously granted restricted stock units (RSUs) to cover tax withholding obligations when those RSUs vested and were settled.

After this tax-related share withholding, the CFO beneficially owns 388,273 common shares, held directly. The filing indicates this was an administrative equity compensation event, not an open-market purchase or sale.

Insider Trade Summary

Exercise Price or Tax Liability: 1,235 shares

Exercise Price or Tax Liability 1 txn

Insider Pulik Richard

Role CFO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Shares	1,235	$20.27	$25K

Holdings After Transaction: Common Shares — 388,273 shares (Direct)

Footnotes (1)

1. F1. Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Roivant Sciences (ROIV) disclose in this Form 4?

The Form 4 reports that the CFO had 1,235 common shares withheld on 11/20/2025 as a net settlement of previously granted RSUs to satisfy tax withholding obligations tied to RSU vesting and settlement.

Who is the reporting person in the Roivant Sciences (ROIV) Form 4 and what is their role?

The reporting person is the Chief Financial Officer (CFO) of Roivant Sciences Ltd., identified as an officer of the issuer in the filing.

At what price were the Roivant Sciences (ROIV) shares withheld for tax purposes?

The 1,235 common shares were withheld at a price of $20.27 per share in connection with the RSU net settlement.

How many Roivant Sciences (ROIV) shares does the CFO own after this transaction?

Following the reported transaction, the CFO beneficially owns 388,273 Roivant Sciences common shares, held directly.

Was the Roivant Sciences (ROIV) insider transaction an open-market trade?

No. The explanation states it was a net settlement of previously granted RSUs by the issuer to cover applicable tax withholding obligations when those RSUs vested, rather than an open-market purchase or sale.

What is the transaction date in the Roivant Sciences (ROIV) Form 4?

The earliest transaction date reported is 11/20/2025, which is when the net settlement of RSUs and share withholding occurred.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/24/2025 - 09:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pulik Richard

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON X0 SW1H 0DB

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	11/20/2025		F		1,235(1)	D	$20.27	388,273	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

	By: /s/ Jo Chen, as Attorney-in-Fact for Richard Pulik	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.